The global Digital PCR and Real-Time PCR Market Size is valued at 8.29 billion in 2022 and is predicted to reach 16.43 billion by the year 2031 at an 8.02% CAGR during the forecast period for 2023-2031.
Digital PCR is an end-point PCR method for absolute quantification and analyzing minority sequences against a backdrop of similar majority sequences. Digital PCR (dPCR) allows for the exact and sensitive measurement of nucleic acids. Real time PCR is a method for collecting data during the PCR process, integrating amplification and detection into a single phase. Nucleic acid quantification using real-time quantitative PCR is sensitive, specific, and repeatable. It monitors the amplification of a specific DNA molecule throughout the PCR.
The rising prevalence of genetic disorders and major infectious diseases, increased use of biomarker profiling for disease diagnosis, and the successful completion of the Human Genome Project are the primary factors driving demand for technologically advanced PCR tests during the forecast period. Significant technological developments, increased investments, funding, and grants are expected to raise demand for digital PCR in various applications in the next years.
However, the COVID-19 pandemic has significantly impacted the healthcare industry. Digital PCR and real-time PCR have generated considerable interest due to their use in diagnostics and drug discovery. Therefore, industry suppliers are actively developing droplet digital PCR assays for COVID-19 detection. In addition, numerous participants in the industry have developed unique instruments and tests for COVID-19 testing.
Competitive Landscape:
Some of the Digital PCR and Real-Time PCR Market players are:
- Abbott Laboratories
- Agilent Technologies, Inc.
- Analytik Jena AG
- Becton Dickinson and Company
- Bio Molecular Systems
- Biomeme Inc.
- Biomérieux S.A.
- Bioneer Corporation
- Bio-Rad Laboratories, Inc.
- Cole-Parmer Instrument Company Llc
- Danaher Corporation
- Elitech Group Sas
- Endress+Hauser
- Enzo Life Sciences, Inc.
- Eppendorf AG
- Hoffmann-LA Roche Ltd.
- Fluidigm Corporation
- JN Medsys PTE, LTD.
- Merck KGAA
- Meridian Bioscience, Inc.
- Promega Corporation
- Qiagen N.V.
- Quidel Corporation
- Quanta Biosciences Inc.
- Sacace Biotechnologies Srl
- Standard Biotools
- Stilla Technologies
- Takara Bio, Inc.
- Thermo Fisher Scientific, Inc.
Market Segmentation:
The digital PCR and real-time PCR market is segmented on the basis of product & service, application, and end-user. The product & service segment includes QPCR (QPCR reagents and consumables, QPCR instruments, QPCR software and services), DPCR (DPCR reagents and consumables, DPCR instruments, DPCR software and services). DPCR instruments are further segmented into chip-based digital PCR and beaming digital PCR. On the basis of QPCR application, the market is segmented into clinical applications (infectious disease testing, oncology testing, blood screening, transplant diagnostics, other clinical applications), research applications, forensic applications, environmental applications, and other applications. The end-user segment includes Hospitals and diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology, CROS & CDMOS, forensic laboratories, and other end-users.
Based on dPCR & qPCR end-users, the Hospitals And Diagnostic Laboratories Segment Is Accounted As A Major Contributor In The Digital PCR And Real-Time PCR Market
The hospitals and diagnostic laboratories category is expected to hold a considerable share in the global Digital PCR and Real-Time PCR Market in 2022 owing to the rising availability of qPCR reagents in the market. The use of clinical diagnostics and the continual growth of healthcare infrastructure in emerging markets, and the increasing prevalence and incidence of target diseases such as HIV/AIDS, cancer, malaria, and tuberculosis are likely to drive demand for hospital and diagnostic facilities in the Digital PCR (dPCR) and Real-Time PCR (qPCR) markets. The growing awareness among End-Users about the benefits of qPCR ineffective and speedy illness diagnosis is projected to fuel the growth of the Digital PCR (dPCR) and Real-Time PCR (qPCR) Markets in the coming years.
qPCR & dPCR reagents and consumables segment witness growth at a rapid rate
The QPCR & DPCR reagents and consumables segment is projected to expand at a rapid rate in the global Digital PCR and Real-Time PCR Market. This can be ascribed to the COVID-19 pandemic, increased demand for early illness detection, and the number of prominent companies producing digital PCR consumables and reagents. Furthermore, the widespread usage of consumables and reagents and the growing demand for healthcare, research, and other uses contribute to the segment's substantial share. Furthermore, the category is expected to keep its lead during the forecast period.
In The Region, The North America Digital PCR And Real-Time PCR Market Holds A Significant Revenue Share
The North America Digital PCR and Real-Time PCR Market is expected to register the highest market share in terms of revenue in the near future, primarily due to the presence of favourable rules and many government efforts aimed at developing healthcare infrastructure, as well as the region's high disease prevalence. Furthermore, the region's strong presence of significant manufacturers and an increasing need for rapid diagnostic tests are projected to be critical factors driving the North American market throughout the projection period.
Due to the significant developments by China and Japan for technological integration of PCR methodologies, as well as the development of healthcare, R&D, and clinical development frameworks by emerging economies such as India and Australia, Asia Pacific is the most lucrative market. Throughout the projection period, the industry will see profitable growth possibilities.
Digital PCR and Real-Time PCR Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 8.29 Bn |
|
Revenue forecast in 2031 |
USD 16.43 Bn |
|
Growth rate CAGR |
CAGR of 8.02 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product & Service, Application, And End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Danaher Corporation, F. Hoffmann-LA Roche Ltd., Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Takara Bio Inc., Becton, Dickson and Company, Abbott Laboratories, Promega Corporation, Merck KGAA, Endress+Hauser, Biomerieux, Meridian Bioscience, Eppendorf AG, Quidel Corporation, Standard Biotools, Enzo Biochem, Inc., Stilla Technologies, JN Medsys PTE, LTD. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
